Our findings demonstrated that metformin significantly decreased the TLR4 level on monocytes originating from all NAFLD patients in a dose-dependent manner; however, its efficacy depended largely on the presence of obesity. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.